山东大学学报 (医学版) ›› 2023, Vol. 61 ›› Issue (6): 47-52.doi: 10.6040/j.issn.1671-7554.0.2023.0099
• 临床医学 • 上一篇
李夕凤,李红梅
LI Xifeng, LI Hongmei
摘要： 目的 探讨抗N-甲基-D-天冬氨酸受体(NMDAR)脑炎相关的炎性生物标志物,为临床提供帮助。 方法 收集18例抗NMDAR脑炎(抗NMDAR脑炎组)、12例抗富含亮氨酸胶质瘤失活蛋白1(LGI1)抗体脑炎(抗LGI1抗体脑炎组)、12例对照组患者的血清及脑脊液标本,采用酶联免疫吸附试验(ELISA)法检测各组血清及脑脊液C-X-C基序配体10(CXCL10)水平,采用SPSS 26.0软件进行数据统计分析,分别比较抗NMDAR脑炎组与对照组、抗LGI1抗体脑炎组与对照组、抗NMDAR脑炎组与抗LGI1抗体脑炎组脑脊液及血清CXCL10水平差异,分析CXCL10水平与抗NMDAR脑炎患者临床指标的相关性。 结果 抗NMDAR脑炎组脑脊液CXCL10水平明显高于对照组［168.29 pg/mL(126.74 pg/mL)vs 82.11 pg/mL(43.61 pg/mL),P=0.003］,抗NMDAR脑炎组脑脊液CXCL10水平明显高于抗LGI1抗体脑炎组［168.29 pg/mL(126.74 pg/mL)vs 75.72 pg/mL(83.39 pg/mL),P=0.008］。抗NMDAR脑炎患者脑脊液CXCL10水平与脑脊液IgM水平呈正相关(相关系数rs=0.630,P=0.007)。 结论 脑脊液CXCL10是抗NMDAR脑炎潜在的生物标志物,且存在一定特异性。
中图分类号:
| [1] Dalmau J, Graus F. Antibody-mediated encephalitis [J]. N Engl J Med, 2018, 378(9): 840-851. [2] Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma [J]. Ann Neurol, 2007, 61(1): 25-36. [3] Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis [J]. Lancet Neurol, 2011, 10(1): 63-74. [4] Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis [J]. Lancet Neurol, 2016, 15(4): 391-404. [5] 中华医学会神经病学分会. 中国自身免疫性脑炎诊治专家共识[J]. 中华神经科杂志, 2017, 50(2): 91-98. Expert consensus on diagnosis and treatment of autoimmune encephalitis in China [J]. Chinese Journal of Neurology, 2017, 50(2): 91-98. [6] Liu JW, Liu L, Kang WT, et al. Cytokines/chemokines: potential biomarkers for non-paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis [J]. Front Neurol, 2020, 11: 582296. doi: 10.3389/fneur.2020.582296. [7] Gresa-Arribas N, Titulaer MJ, Torrens A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study [J]. Lancet Neurol, 2014, 13(2): 167-177. [8] Dalmau J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 Cotzias Lecture [J]. Neurology, 2016, 87(23): 2471-2482. [9] Jones BE, Tovar KR, Goehring A, et al. Autoimmune receptor encephalitis in mice induced by active immunization with conformationally stabilized holoreceptors [J]. Sci Transl Med, 2019, 11(500): eaaw0044. doi: 10.1126/scitranslmed.aaw0044. [10] Deng B, Liu XN, Li X, et al. Raised cerebrospinal fluid BAFF and APRIL levels in anti-N-methyl-D-aspartate receptor encephalitis: correlation with clinical outcome [J]. J Neuroimmunol, 2017, 305: 84-91. doi:10.1016/j.jneuroim.2017.01.02. [11] Liba Z, Kayserova J, Elisak M, et al. Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid [J]. J Neuroinflammation, 2016, 13(1): 55. [12] Leypoldt F, Höftberger R, Titulaer MJ, et al. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response [J]. JAMA neurol, 2015, 72(2): 180-186. [13] Kothur K, Wienholt L, Mohammad SS, et al. Utility of CSF cytokine/chemokines as markers of active intrathecal inflammation: comparison of demyelinating, anti-NMDAR and enteroviral encephalitis [J]. PLoS One, 2016, 11(8): e0161656. doi: 10.1371/journal.pone.0161656. [14] Dao LM, Machule ML, Bacher P, et al. Decreased inflammatory cytokine production of antigen-specific CD4(+)T cells in NMDA receptor encephalitis [J]. J Neurol, 2021, 268(6): 2123-2131. [15] Kothur K, Wienholt L, Brilot F, et al. CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review [J]. Cytokine, 2016, 77: 227-237. doi:10.1016/j.cyto.2015.10.001. [16] Zlotnik A, Yoshie O. The chemokine superfamily revisited [J]. Immunity, 2012, 36(5): 705-716. [17] Lebre MC, Burwell T, Vieira PL, et al. Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation [J]. Immunol Cell Biol, 2005, 83(5): 525-535. [18] Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells(Th1s)and Th2s [J]. J Exp Med, 1998, 187(1): 129-134. [19] Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine(C-X-C motif)ligand(CXCL)10 in autoimmune diseases [J]. Autoimmun Rev, 2014, 13(3): 272-280. [20] Sørensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients [J]. J Clin Invest, 1999, 103(6): 807-815. [21] Yamamoto J, Adachi Y, Onoue Y, et al. Differential expression of the chemokine receptors by the Th1- and Th2-type effect populations within circulating CD4+ T cells [J]. J Leukoc Biol, 2000, 68(4): 568-574. [22] Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes [J]. J Leukoc Biol, 1997, 61(3): 246-257. [23] Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant(I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3 [J]. J Exp Med, 1998, 187(12): 2009-2021. [24] Hsieh MF, Lai SL, Chen JP, et al. Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus [J]. J Immunol, 2006, 177(3): 1855-1863. [25] Dufour JH, Dziejman M, Liu MT, et al. IFN-gamma-inducible protein 10(IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking [J]. J Immunol, 2002, 168(7): 3195-3204. [26] Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis [J]. Neurology, 2011, 77(6): 589-593. [27] Byun JI, Lee ST, Moon J, et al. Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-d-aspartate receptor encephalitis [J]. J Neuroimmunol, 2016, 297: 141-147. doi:10.1016/j.jneuroim.2016.05.023. [28] Fife BT, Kennedy KJ, Paniagua MC, et al. CXCL10(IFN-gamma-inducible protein-10)control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis [J]. J Immunol, 2001, 166(12): 7617-7624. [29] Roberts WK, Blachère NE, Frank MO, et al. A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease [J]. Ann Neurol, 2015, 78(4): 619-629. [30] Müller M, Carter S, Hofer MJ, et al. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity:a tale of conflict and conundrum [J]. Neuropathol Appl Neurobiol, 2010, 36(5): 368-387. [31] Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium [J]. Clin Immunol, 2001, 98(1): 39-45. [32] Narumi S, Takeuchi T, Kobayashi Y, et al. Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus [J]. Cytokine, 2000, 12(10): 1561-1565. [33] Fujii H, Shimada Y, Hasegawa M, et al. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis [J]. J Dermatol Sci, 2004, 35(1): 43-51. [34] Antonelli A, Ferrari SM, Corrado A, et al. CXCR3, CXCL10 and type 1 diabetes [J]. Cytokine Growth Factor Rev, 2014, 25(1): 57-65. [35] Muehlinghaus G, Cigliano L, Huehn S, et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells [J]. Blood, 2005, 105(10): 3965-3971. [36] Tüzün E, Zhou L, Baehring JM, et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma [J]. Acta Neuropathol, 2009, 118(6): 737-743. [37] Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases [J]. Ann Neurol, 2012, 72(2): 241-255. [38] Huijbers MG, Querol LA, Niks EH, et al. The expanding field of IgG4-mediated neurological autoimmune disorders [J]. Eur J Neurol, 2015, 22(8): 1151-1161. [39] Hashizume M, Tan SL, Takano J, et al. Tocilizumab, A humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights [J]. Int Rev Immunol, 2015, 34(3): 265-279. [40] Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study [J]. Neurology, 2014, 82(15): 1302-1306. |
| [1] | 侯少瑾,王云凤,曹丽丽,刘学伍,赵秀鹤,王胜军. 视神经脊髓炎谱系疾病53例与多发性硬化11例的脑脊液检测比较[J]. 山东大学学报 (医学版), 2023, 61(1): 32-37. |
| [2] | 苗萌,贾国勇,刘颖,王翠兰. 36例成人流行性乙型脑炎临床分析和影像学特点[J]. 山东大学学报 (医学版), 2018, 56(2): 23-27. |
| [3] | 王春来, 徐淑军, 王洪亮, 尚景瑞. 神经内镜下外伤性脑脊液鼻漏修补的临床研究[J]. 山东大学学报（医学版）, 2015, 53(3): 69-72. |
| [4] | 黄景阳1，杨承慧1，马坤润1，刘曦1，王逸飞1，陈海丽1，刘宝义2，袁中瑞1. HMGB1介导急性高血糖对脑缺血大鼠血-脑脊液屏障的损伤[J]. 山东大学学报(医学版), 2013, 51(9): 17-21. |
| [5] | 曹伟，辛涛，刘威，张永超. 桥小脑角区肿瘤术后隐匿性脑脊液漏临床分析[J]. 山东大学学报(医学版), 2013, 51(12): 78-81. |
| [6] | 屈传强1，焉传祝2，陈裴3，王翠兰3，郭洪志2. 基质金属蛋白酶在脑白质疏松症血-脑脊液屏障机制中的实验研究[J]. 山东大学学报(医学版), 2012, 50(10): 23-27. |
| [7] | 秦延江,刘师莲,杨银荣,柏淑美,张旭华,邓小梅 . 中枢神经系统脱髓鞘疾病脑脊液蛋白质组学研究[J]. 山东大学学报(医学版), 2008, 46(1): 9-14. |
| [8] | 李敏,王翠兰,邓小梅,李季春,姜勇,苏传生,张安新 . Mollaret脑膜炎脑脊液细胞学研究[J]. 山东大学学报(医学版), 2007, 45(8): 862-863. |
|
||
